Dr. Enzinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6855Fax+1 617-632-5370- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of RochesterResidency, Internal Medicine, 1992 - 1995
The Warren Alpert Medical School of Brown UniversityClass of 1992
Certifications & Licensure
MA State Medical License 1999 - 2025
NY State Medical License 1995 - 2006- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Avastin and Taxotere for Esophagogastric Cancer Start of enrollment: 2004 Aug 01
- Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer Start of enrollment: 2002 Jan 01
- Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer Start of enrollment: 2001 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada L...> ;NPJ Precision Oncology. 2024 Apr 8
- 1 citationsBemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIG...Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Erika...> ;Gastric Cancer. 2024 May 1
- 46 citationsZolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen...> ;Nature Medicine. 2023 Aug 1
- Join now to see all
Press Mentions
Merck, Roche and Bristol Myers Nab 4 of 6 Positive ODAC Votes for ‘Dangling’ Accelerated ApprovalsApril 29th, 2021- FDA Approves Pembrolizumab plus Platinum- & Fluoropyrimidine-Based Chemotherapy for Treatment of Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaMarch 23rd, 2021
- FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaMarch 23rd, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Boston Children's HospitalBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Salem HospitalSalem, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
